Basilea Pharmaceutica AG asked European regulators Thursday to reconsider an application for its antibiotic-resistant staph infection treatment.
On Feb. 18, the European Committee for Medicinal Products for Human Use refused to approve the antibiotic ceftobiprole.
Johnson & Johnson then ended its partnership with Basilea.
The Food and Drug Administration rejected the antibiotic in December.
Switzerland's Basilea has full rights to the antibiotic, which has been approved in Canada and Switzerland.